## ARWR: Arrowhead Pharmaceuticals, Inc. - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_20 at 9.3% in upper entry zone (4.0-10.0%), top 5% cross-sectional ranking. Short-term MRS_5 (2.2%) confirms momentum alignment. Outperforming sector by 9.4%. Caution: momentum weakening (-4.1% MRS).

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($60.76)
- **If Wrong:** Exit if MRS_20 drops below entry zone or breaks stop
- **Invalidation:** MRS_20 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 2
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Christopher Richard Anzalone Sells 85,000 Shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock**
- Source: MarketBeat | 20251220T000847 | Neutral | Relevance: 100%
- Christopher Richard Anzalone, CEO of Arrowhead Pharmaceuticals (NASDAQ:ARWR), sold 85,000 shares of the company's stock for over $5.4 million on December 17th. This sale is part of combined transactions over three days totaling 269,298 shares sold for approximately $17.79 million. Following the sale, Anzalone still owns 3,831,957 shares valued at about $245.4 million, and analysts have a "Moderate Buy" consensus rating with various price target increases.

**2. Arrowhead Pharmaceuticals, Inc. $ARWR Holdings Boosted by Assenagon Asset Management S.A.**
- Source: MarketBeat | 20251220T080847 | Somewhat-Bullish | Relevance: 100%
- Assenagon Asset Management S.A. significantly increased its stake in Arrowhead Pharmaceuticals, Inc. ($ARWR) by 1,388.6% in the third quarter of 2025, now holding 380,625 shares valued at $13.13 million. Despite this institutional vote of confidence, company insiders, including CEO Christopher Anzalone, have engaged in substantial share sales totaling nearly $20 million in the past quarter. Arrowhead Pharmaceuticals, a clinical-stage biopharmaceutical company focused on RNAi therapeutics, currently holds a "Moderate Buy" consensus rating from analysts with an average target price of $61.89.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 6, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-17 | Piper Sandler | $100 | $70 | +43% |
| 2025-12-11 | RBC Capital | $80 | $52 | +54% |
| 2025-12-09 | B of A Securiti | $81 | $62 | +31% |
| 2025-12-02 | HC Wainwright & | $85 | $80 | +6% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-17 | Piper Sandler | main | Overweight |
| 2025-12-11 | RBC Capital | main | Outperform |
| 2025-12-09 | B of A Securiti | main | Buy |
| 2025-12-02 | HC Wainwright & | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 8 ($0.00M) |
| Sells | 5 ($3.67M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 54.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 1 |

**Top Holders:**
- Blackrock Inc.: 14.9% (+4.1%)
- Vanguard Group Inc: 11.8% (+3.3%)
- Avoro Capital Adviso: 8.0% (+2.8%)
- State Street Corpora: 4.7% (+0.4%)
- FMR, LLC: 4.2% (+11.4%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-4.1% 5d) with bearish MACD, trend may be turning.
2. Insider selling cluster: $3.7M in recent transactions.
3. Elevated short interest (11.3%): bears positioning against stock.

### Catalysts

- Analyst target momentum: 6 raises (avg +31%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

Balance sheet: strong liquidity (4.9x). Revenue declining -31% YoY, concerning. Analyst sentiment positive (6 raises, avg +31%). Insider selling cluster ($3.7M in 90 days), potential headwind. Institutional flow bullish (8 buying vs 1 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $9.5B |
| Beta | 1.29 |
| 52W Range | $9.57 - $72.36 |
| Short Interest | 11.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -1.32 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_20 deteriorating from 13.4% to 9.3% (-4.1% in 5 days), indicating relative weakness vs NASDAQ. Currently in upper STRENGTH zone (4.0-10.0%), cross-sectional ranking at 95th percentile. MRS_5 at 2.2% confirms short-term momentum alignment. AM_20 at 9.9% shows strong absolute momentum above own 20MA. Outperforming sector by 9.4pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: +STL (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 9.32% (CS: 95) | Strong |
| RSI_14 | 68.6 | Neutral |
| MACD Histogram | -0.45 | Bearish |
| vs SMA20 | 1.099x | Above |
| vs SMA50 | 1.417x | Above |
| vs SMA200 | 2.625x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $69.00
- **Stop Loss:** $60.76 (11.9% risk)
- **Target:** $81.36 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 145
- **Position Value:** $10,005.00
- **Portfolio %:** 10.01%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite. VIX decline to 52-week lows and moderate breadth recovery suggest calming conditions, though narrow participation indicates selectivity remains key. Positive earnings momentum and AI adoption themes provide fundamental support for quality growth names.*

### Earnings

**Next:** 2026-02-09 (Est: $-0.10)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-0.16 | $-0.18 | -14.4% |
| 2025Q2 | $-1.10 | $-1.26 | -14.4% |
| 2025Q1 | $-0.46 | $2.75 | +695.0% |
| 2024Q4 | $-0.72 | $-1.39 | -92.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*